Health TrialsbyHealthPanel

Role of Amlodipine in Reduction of CIN

ConditionContrast-induced Nephropathy
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-70
SponsorMinia University

About this trial

The aim is to assess the benefit of low dose oral amlodipine in renal protection from contrast induced nephropathy in diabetic patients in intensive care unit

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

adult patients of both sexes (18:70) diabetic patients with serum creatinine below 1.2 hemodynamically stable patients ASA physical status 2,3

Disqualifiers

patient refusal patients of chronic kidney diseases NPO patients serum creatinine above 1.2 Hypertensive patients

Trial design

Design model

Parallel

Treatments tested in this trial

  • Calcium channel blocker

    Drug

    amlodipine group will receive low dose oral amlodipine ( 5 mg ) before iv contrast and every 12 hour for 48 hour

  • Hydration

    Other intervention

    before the procedure patients will recieve iv bolus of 250 ml saline followed by continous infusion of 100 ml/h of normal saline

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Control groupOther 1 intervention
Group B: Amlodipine groupOther 2 interventions

Trial outcomes

Primary outcomes

1

measuring serum creatinine level

measuring serum creatinine level before the procedure and every day for 48 hours after

Time frame
baseline

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Minia University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: